Earnings Call · Q3 FY2022·2022-11-12

Q3 22EPS -10.45%·Rev n/aQ2 22EPS -68.42%·Rev n/aQ1 22EPS +6.25%·Rev n/aQ4 21EPS -10.53%·Rev n/a⚠ consensus missing

Processa Pharmaceuticals, Inc. PCSA

Jim Stanker — Likely an executive or senior management, possibly CFO or IR

David Young — Likely an executive or senior management, possibly CEO or Chief Medical Officer

+1.9%1d on move date+1.4% vs SPY3d+2.8%5d+0.5%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more PCSA calls or request research access.

More PCSA calls Browse calls Request research access